EXEL:NASDAQ
Exelixis Inc
$57.43
arrow_downward
-1.54%(-0.90) 1D
$57.40
arrow_downward
-0.05% (-0.030)todayPre-market
Closed: Sep 10, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$58.33
High
$58.33
Low
$57.23
Mkt. cap
14.23B
Avg. vol.
2.50M
Volume
4.52K
P/E ratio
18.04
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
Open
$58.33
High
$58.33
Low
$57.23
Mkt. cap
14.23B
Avg. vol.
2.50M
Volume
4.52K
P/E ratio
18.04
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
News stories
From web sources and news partners
Simply Wall Street
·
14 hours ago
Exelixis (EXEL) Stock Looks Undervalued On Earnings But Mixed On Value
Investing.com
·
1 day ago
Exelixis at Citigroup summit: building a second growth engine
Stock Titan
·
1 day ago
A cancer-drug milestone brings Adagene a $2 million payment
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com